Loading
Annovis Bio, Inc. is a clinical-stage biopharmaceutical company focused on pioneering treatments for neurodegenerative disorders. The firm's flagship drug, Buntanetap, an oral medication, has successfully advanced through Phase 2a clinical trials for Alzheimer's and Parkinson's diseases. This compound is also currently being evaluated in clinical studies for Alzheimer's disease in individuals with Down Syndrome, as well as for various other chronic neurodegenerative conditions. Beyond Buntanetap, Annovis Bio is developing ANVS405 to offer protection against traumatic brain injury and stroke. Additionally, ANVS301 is progressing through Phase I clinical trials, aiming to enhance cognitive capabilities in the later stages of Alzheimer's disease and broader dementia. The company was founded in 2008 and operates out of Berwyn, Pennsylvania.
Latest quote
$1.17
−$0.04 · -3.31%
Regular session · ET · Market data may be delayed.
Annovis Bio, Inc. is a clinical-stage biopharmaceutical company focused on pioneering treatments for neurodegenerative disorders. The firm's flagship drug, Buntanetap, an oral medication, has successfully advanced through Phase 2a clinical trials for Alzheimer's and Parkinson's diseases. This compound is also currently being evaluated in clinical studies for Alzheimer's disease in individuals with Down Syndrome, as well as for various other chronic neurodegenerative conditions. Beyond Buntanetap, Annovis Bio is developing ANVS405 to offer protection against traumatic brain injury and stroke. Additionally, ANVS301 is progressing through Phase I clinical trials, aiming to enhance cognitive capabilities in the later stages of Alzheimer's disease and broader dementia. The company was founded in 2008 and operates out of Berwyn, Pennsylvania.
Regular session · ET · Market data may be delayed.
GoAI Score
Sell
Valuation
26
Expensive
Sentiment
54
Mixed
Risk
70
High Risk
Momentum
26
Weakening
Full GoAI research
Thesis, catalysts, evidence, and risk analysis.
Annovis Bio, Inc. is a clinical-stage biopharmaceutical company focused on pioneering treatments for neurodegenerative disorders. The firm's flagship drug, Buntanetap, an oral medication, has successfully advanced through Phase 2a clinical trials for Alzheimer's and Parkinson's diseases. This compound is also currently being evaluated in clinical studies for Alzheimer's disease in individuals with Down Syndrome, as well as for various other chronic neurodegenerative conditions. Beyond Buntanetap, Annovis Bio is developing ANVS405 to offer protection against traumatic brain injury and stroke. Additionally, ANVS301 is progressing through Phase I clinical trials, aiming to enhance cognitive capabilities in the later stages of Alzheimer's disease and broader dementia. The company was founded in 2008 and operates out of Berwyn, Pennsylvania.
Operating income
Net income
| Metric (USD) | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Research and development | 25.22M USD | 20M USD | 38.79M USD | 16.52M USD | 8.48M USD |
| Selling, general, and administrative | 4.48M USD | 6.7M USD | 6.24M USD | 9M USD | 6.06M USD |
| Operating expenses | 29.7M USD | 26.69M USD | 45.04M USD | 25.51M USD | 14.54M USD |
| Interest income | 699.06K USD | 331.85K USD | 667.9K USD | 182.71K USD | 13.34K USD |
| Interest expense | — | 1.85M USD | — | — | — |
| Operating income | −29.7M USD | −26.69M USD | −45.04M USD | −25.51M USD | −14.54M USD |
| Net income | −28.85M USD | −24.59M USD | −56.2M USD | −25.33M USD | −14.49M USD |
Company facts updated Oct 9, 2026.
Recent quarterly results
AI-generated and delayed market data for informational and educational purposes only. Not investment advice.
